University of California, Los Angeles psychedelic research trials
Data as of 11 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
University of California, Los Angeles is listed with 7 registered studies counted here, in Los Angeles, United States. By compound: 4 psilocybin, 2 MDMA and 1 ketamine. By registry status: 2 recruiting, 1 not yet recruiting, 2 completed, 1 suspended and 1 withdrawn. By phase: 1 early phase 1, 4 phase 1 and 2 phase 2. Reported start years run from 2014 (earliest) to 2027 (latest).
Institution name, city and country are copied from the research site linked to each registry record. A study counts once per institution, and a study tagged with more than one compound is counted under each compound.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
At a glance
- 7 registered studies are counted on this page.
By compound
| Compound hub | Studies |
|---|---|
| Psilocybin | 4 |
| MDMA | 2 |
| Ketamine | 1 |
By registry status
| Status | Studies | Share |
|---|---|---|
| Recruiting | 2 | 29% |
| Not yet recruiting | 1 | 14% |
| Completed | 2 | 29% |
| Suspended | 1 | 14% |
| Withdrawn | 1 | 14% |
By phase
| Phase | Studies | Share |
|---|---|---|
| Early Phase 1 | 1 | 14% |
| Phase 1 | 4 | 57% |
| Phase 2 | 2 | 29% |
Registered studies
All counted studies, newest start first. The order is not a ranking and says nothing about quality. Titles are quoted from the registry. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.
| Title as registered | Registry ID | Status | Phase | Start | Compound |
|---|---|---|---|---|---|
| Group PACBT for Depression | NCT07566104 | Not yet recruiting | Phase 2 | 2027-01-01 | Psilocybin |
| Safety Profile of Psilocybin for Cocaine Use Disorder | NCT06102434 | Suspended | Early Phase 1 | 2026-02-01 | Psilocybin |
| RCT of Psilocybin-assisted CBT for Depression | NCT07281352 | Recruiting | Phase 1 | 2026-01-05 | Psilocybin |
| MDMA-Assisted Psychotherapy for Treatment Resistant PTSD in Adolescents | NCT06353282 | Withdrawn | Phase 2 | 2025-07-01 | MDMA |
| Tolerability of MDMA in Schizophrenia | NCT05770375 | Recruiting | Phase 1 | 2025-04-01 | MDMA |
| Psilocybin-assisted CBT for Depression | NCT05227612 | Completed | Phase 1 | 2023-06-27 | Psilocybin |
| Biomarkers of Fast Acting Therapies in Major Depression | NCT02165449 | Completed | Phase 1 | 2014-06-01 | Ketamine |
About this data
Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals. A registry listing is not evidence of safety, benefit or results.
Substance hubs for these compounds
Psilocybin | MDMA | Ketamine